Senators Pursue $35 Insulin Cap for Private Insurance and Uninsured
U.S. senators are advancing legislation to extend the $35 insulin cost cap beyond Medicare to cover private insurance and uninsured individuals. The Medicare cap, enacted under the Inflation Reduction Act, currently applies only to Medicare Part D beneficiaries. The proposed expansion would affect Medicaid managed care organizations that coordinate care for dual-eligible beneficiaries and states with Medicaid pharmacy carve-ins where commercial insulin pricing dynamics affect beneficiary access. No effective date or legislative timeline is specified in the report.
If enacted, MCOs managing pharmacy benefits would face new insulin pricing requirements that could affect formulary design, pharmacy network contracts, and coordination with commercial insurers for dual-eligible populations.
Pharmacy · Managed Care
You might also like